KPTI · Karyopharm Therapeutics Inc.
$1.95
+0.04 (+1.83%)
At close · Aug 6
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$43.29M
Shares
22.66M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | CEO | $2,320,902 |
| Reshma Rangwala | Chief Medical Officer | $2,016,134 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,399,580 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | CEO | $2,069,341 |
| Reshma Rangwala | Chief Medical Officer | $1,124,444 |
| Sohanya Cheng | Senior Vice President, Sales and Commercial Operations | $1,094,829 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | CEO | $2,626,288 |
| Reshma Rangwala | Chief Medical Officer | $1,227,789 |
| Sohanya Cheng | Senior Vice President, Sales and Commercial Operations | $1,193,414 |
| Michael Mason | CFO | $1,139,312 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,109,115 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | CEO | $6,910,015 |
| Sharon Shacham | President and Chief Scientific Officer | $6,037,789 |
| Michael Mason | CFO | $2,699,032 |
| Chief Commercial | Officer | $2,612,718 |
| Sohanya Cheng | Senior Vice President, Sales and Commercial Operations | $2,612,718 |
| Ran Frenkel | Former Executive Vice President, Chief Development Officer | $2,160,250 |
| Michael Mano | Senior Vice President, General Counsel and Secretary | $2,060,407 |
| Chief Development | Officer | $1,795,247 |
| Stuart Poulton | Executive Vice President, Chief Development Officer | $1,779,848 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Richard Paulson | CEO | $8,355,172 |
| Sharon Shacham | President and Chief Scientific Officer | $3,106,591 |
| Michael Kauffman | CEO | $3,069,589 |
| Michael Mason | CFO | $1,744,578 |
| Jatin Shah | Chief Medical Officer | $1,588,213 |
| Former Chief | Development Officer | $1,577,203 |
| Ran Frenkel | Former Executive Vice President, Chief Development Officer | $1,577,203 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Senior Clinical | CEO | $3,937,039 |
| Michael Kauffman | CEO | $3,937,039 |
| Sharon Shacham | President and Chief Scientific Officer | $3,670,884 |
| Former Chief | Development Officer | $3,670,884 |
| Chief Scientific | Officer and Former President | $3,670,884 |
| Michael Mason | CFO | $2,266,816 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Michael Kauffman | CEO | $3,231,504 |
| Senior Clinical | CEO | $3,231,504 |
| Sharon Shacham | President and Chief Scientific Officer | $3,020,459 |
| Chief Scientific | Officer and Former President | $3,020,459 |
| Christopher Primiano | General Counsel | $1,623,347 |
| Michael Mason | CFO | $956,697 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Kauffman | CEO | $2,274,945 |
| Sharon Shacham | President and Chief Scientific Officer | $2,089,383 |
| Christopher Primiano | General Counsel | $1,522,593 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christy J. Oliger | Class I director | Appointed | 2026-05-28 |
| Barry E. Greene | Class I director | Appointed | 2026-05-28 |
| Mansoor Raza Mirza, M.D. | member of the Board of Directors | Resigned | 2025-09-11 |
| Zhen Su, M.D., M.B.A. | Class III director | Appointed | 2025-05-29 |
| Garen G. Bohlin | Class III director | Appointed | 2025-05-29 |
| Lori Macomber | Executive Vice President, Chief Financial Officer and Treasurer | Appointed | 2025-01-02 |
| Kristin Abate | principal accounting officer | Appointed | 2024-11-20 |
| Kristin Abate | Vice President, Chief Accounting Officer, and Assistant Treasurer | Appointed | 2024-11-20 |
| Michael Mason | Executive Vice President, Chief Financial Officer and Treasurer | Resigned | 2024-08-29 |
| Richard Paulson | Class II director | Appointed | 2024-05-31 |
| Chen Schor | Class II director | Appointed | 2024-05-31 |
| Deepika R. Pakianathan | Class II director | Appointed | 2024-05-31 |
Key facts
CIK
1503802
CUSIP
48576U205
13F (30d)
14 filings
14 filers
Visit website
Investor relations